Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (241-250 of 284) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Class 1, 2, and 3 <i>BRAF</i>-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular CharacterizationMarta Schirripa, Paola Biason, Sara Lonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control StudyFilippo Pietrantonio, Giovanni Fucà, Federica Morano, et al.
JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.
JAMA Oncology|July 4, 2019
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialFilippo Pietrantonio, Federica Morano, Salvatore Corallo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database studyKazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
British Journal of Cancer|September 3, 2019
CK7 and consensus molecular subtypes as major prognosticators in <sup>V600E</sup>BRAF mutated metastatic colorectal cancerFotios Loupakis, Paola Biason, Alessandra Anna Prete, et al.
Therapeutic Advances in Medical Oncology|November 6, 2024
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burdenLeonardo Provenzano, Yong Xiang Gwee, Veronica Conca, et al.
Oncoimmunology|April 7, 2025
Surrogate markers of intestinal dysfunction associated with survival in advanced cancersRoxanne Birebent, Damien Drubay, Carolina Alves Costa Silva, et al.
Pageof 29

Showing results (241-250 of 284) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Class 1, 2, and 3 <i>BRAF</i>-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular CharacterizationMarta Schirripa, Paola Biason, Sara Lonardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2017
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control StudyFilippo Pietrantonio, Giovanni Fucà, Federica Morano, et al.
JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.
JAMA Oncology|July 4, 2019
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialFilippo Pietrantonio, Federica Morano, Salvatore Corallo, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database studyKazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
British Journal of Cancer|September 3, 2019
CK7 and consensus molecular subtypes as major prognosticators in <sup>V600E</sup>BRAF mutated metastatic colorectal cancerFotios Loupakis, Paola Biason, Alessandra Anna Prete, et al.
Therapeutic Advances in Medical Oncology|November 6, 2024
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burdenLeonardo Provenzano, Yong Xiang Gwee, Veronica Conca, et al.
Oncoimmunology|April 7, 2025
Surrogate markers of intestinal dysfunction associated with survival in advanced cancersRoxanne Birebent, Damien Drubay, Carolina Alves Costa Silva, et al.
Pageof 29